The WATCHMAN FLX Pro from Boston Scientific Corp. - left atrial appendage closure gets smoother in cath labs

Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-29, 07:28. Details in the imprint.

The WATCHMAN FLX Pro sits on a tray in the cath lab, a compact metal lattice that feels almost like a miniature spring when Dr. Laura Chen rolls it between gloved fingers. In the heart it becomes something else entirely, a quiet plug intended to keep dangerous clots from escaping.

What the device is for

The WATCHMAN FLX Pro is Boston Scientific Corp.'s latest left atrial appendage closure device for patients with non-valvular atrial fibrillation who need stroke protection but struggle with long-term blood thinners. It is threaded through veins and into the heart via a catheter rather than open-chest surgery.

In practice, the cardiologist pushes the delivery system up from the groin, navigates into the left atrium, then deploys the FLX Pro so it expands and seals the left atrial appendage where clots form. That minimally invasive workflow aims to shorten procedure time and hospital stay compared to more invasive surgical options.

How FLX Pro changes the feel

Compared with earlier WATCHMAN generations, the FLX Pro uses a more rounded frame and broader sealing fabric designed to sit more snugly against the appendage walls. That geometry is meant to reduce the need for repositioning and give operators a more forgiving landing zone when they first release the device.

Operators also get a familiar tactile feedback when they tug gently on the delivery cable to test stability, but reports from early users highlight that the FLX Pro tends to feel more self-assured once anchored, moving less with each heartbeat in fluoroscopy views. That can make the tense few seconds after deployment slightly easier in busy cath labs.

Sizing and everyday workflow

The WATCHMAN FLX Pro typically comes in several diameters so operators can match the device to each patient’s appendage anatomy measured by transesophageal echocardiography or CT. That sizing spread helps keep inventories tidy while still covering a wide range of atrial shapes, from narrow and tubular to broad and chicken-wing configurations.

For staff, the procedural routine is now familiar: prepare the FLX Pro in a sterile tray, flush the delivery sheath, confirm imaging angles, then move through puncture and deployment. Nurses report that the compact packaging and consistent instructions reduce prep-time friction in high-volume labs that may schedule multiple closure cases in a single morning.

Patient experience after implantation

From the patient’s perspective, the FLX Pro is invisible once implanted. What they feel is the recovery: a pressure bandage at the groin access site, the quiet hum of monitors on the ward, and often an overnight stay rather than a prolonged hospital admission.

Many centers transition suitable patients off long-term oral anticoagulants over weeks or months after endothelialization, following structured protocols that combine follow-up imaging and risk assessment. That shift can mean fewer bruises and less anxiety over drug interactions in daily life, though decisions remain individualized.

Safety profile and limitations

No left atrial appendage device is without risk, and clinicians like electrophysiologist Dr. Miguel Alvarez emphasize the need for careful patient selection. Complications such as pericardial effusion, device-related thrombus or incomplete closure still appear in registries and must be weighed against the stroke-prevention benefit.

The FLX Pro’s softer frame and revised anchors are designed to reduce trauma to the appendage wall, yet operators still train extensively on imaging-guided deployment techniques. For patients with complex anatomy or co-morbidities, some centers prefer alternative strategies or maintain anticoagulation rather than pushing device use.

Competition and reimbursement

The WATCHMAN FLX Pro competes in a growing market for structural heart interventions, with rival left atrial appendage devices and emerging pharmacologic strategies vying for share. Hospital purchasing teams look closely at trial data, long-term outcomes and workflow fit before committing to multi-year contracts.

Reimbursement policies vary by country but often hinge on documented stroke risk reduction and cost-offsets from fewer bleeding complications or hospitalizations. Where funding pathways are clear, adoption tends to be brisk; where approvals are slow or tariffs tight, even enthusiastic physicians face sobering budget constraints.

Company context and shares

Boston Scientific Corp. positions the WATCHMAN FLX Pro as part of its structural heart and electrophysiology franchise, alongside devices for atrial fibrillation ablation and valve therapies. That cluster of products aligns with ageing populations and rising cardiovascular disease burdens in key markets.

All told, the WATCHMAN FLX Pro adds another catheter-based tool to Boston Scientific’s menu that both clinicians and investors watch for procedure growth. Boston Scientific shares (ISIN US10117L1017) trade on the New York Stock Exchange under the ticker BSX, reflecting the company’s role as a major global medical-device supplier.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.